Skip to content
Innovative Solutions for Health | Press & Events
Lipocine
  • Pipeline
    • LPCN 1144
    • TLANDO ™
    • TLANDO XR (LPCN 1111)
    • LPCN 1148
    • LPCN 1107
    • LIP’RAL Technology
  • Treated Issues
  • Company
    • Lipocine Management
    • Lipocine Directors
    • Corporate Governance
  • Investors
  • Partnering
  • Contact

Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

  • Email Alerts

Investors:

  • Overview
  • Press Releases
  • Events and Presentations
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Events
  • Presentations
Lipocine Results of LPCN 1154 Pilot Clinical Bridge Study
 Tuesday, May 16, 2023
 8:30am EDT
Listen to the Webcast
logo-white
About
  • Home
  • Treated Issues
  • Company
  • Investors
  • Partnering
Pipeline
  • LPCN 1144
  • TLANDO ™
  • TLANDO XR (LPCN 1111)
  • LPCN 1148
  • LPCN 1107
  • LIP’RAL Technology
Info
  • Careers
  • Press & Events
  • Corporate Presentations
  • Contact
Legal
  • Terms of Use
  • Privacy Policy

© 2019 Lipocine. All Rights Reserved.

Scroll to Top